Immuneering Corp Cl A (IMRX)

Jan 7, 2025, 9:28 AM EST - 10 days ago

Why Is Immuneering Stock Trading Higher On Tuesday?

Dec 19, 2024, 8:00 AM EST - 4 weeks ago

Immuneering Launches Pancreatic Cancer Advisory Board

Dec 13, 2024, 2:10 PM EST - 5 weeks ago

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

FOLD

Dec 12, 2024, 8:00 AM EST - 5 weeks ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Nov 27, 2024, 8:00 AM EST - 7 weeks ago

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Nov 13, 2024, 4:05 PM EST - 2 months ago

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Sep 12, 2024, 4:05 PM EDT - 4 months ago

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Aug 6, 2024, 4:05 PM EDT - 5 months ago

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jul 31, 2024, 4:05 PM EDT - 6 months ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

May 29, 2024, 4:05 PM EDT - 8 months ago

Immuneering to Present at the Jefferies Global Healthcare Conference

May 7, 2024, 4:05 PM EDT - 9 months ago

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

May 6, 2024, 4:30 PM EDT - 9 months ago

Immuneering Recognizes Melanoma Awareness Month

Apr 9, 2024, 12:00 PM EDT - 10 months ago

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Apr 3, 2024, 4:05 PM EDT - 10 months ago

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 27, 2024, 8:00 AM EDT - 10 months ago

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Mar 19, 2024, 2:19 AM EDT - 10 months ago

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Mar 14, 2024, 7:00 AM EDT - 11 months ago

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Mar 12, 2024, 8:00 AM EDT - 11 months ago

Immuneering Appoints Thomas J. Schall, Ph.D.

Mar 11, 2024, 8:00 AM EDT - 11 months ago

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

Mar 6, 2024, 8:00 AM EST - 11 months ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

BLRX CADL ONCY

Mar 5, 2024, 5:00 PM EST - 11 months ago

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

Mar 4, 2024, 8:00 AM EST - 11 months ago

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

Mar 1, 2024, 8:00 AM EST - 11 months ago

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Feb 20, 2024, 8:00 AM EST - 11 months ago

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Feb 1, 2024, 8:00 AM EST - 1 year ago

Immuneering Announces Participation in February Investor Conferences

Dec 12, 2023, 8:00 AM EST - 1 year ago

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Nov 20, 2023, 4:05 PM EST - 1 year ago

Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 9, 2023, 4:05 PM EST - 1 year ago

Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates

Oct 12, 2023, 4:05 PM EDT - 1 year ago

Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

Oct 4, 2023, 4:05 PM EDT - 1 year ago

Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 6, 2023, 8:00 AM EDT - 1 year ago

Immuneering to Present at the Morgan Stanley Healthcare Conference

Aug 3, 2023, 4:05 PM EDT - 1 year ago

Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates

Jul 7, 2023, 5:55 PM EDT - 1 year ago

Immuneering Corp.: Early Stage Promise, But Long-Term Investment

Jun 5, 2023, 8:00 AM EDT - 1 year ago

Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors

May 30, 2023, 8:00 AM EDT - 1 year ago

Immuneering to Present at the Jefferies Healthcare Conference

May 4, 2023, 4:05 PM EDT - 1 year ago

Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates

Apr 18, 2023, 9:24 AM EDT - 1 year ago

Immuneering Announces $30 Million Underwritten Offering

Apr 18, 2023, 9:00 AM EDT - 1 year ago

Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline

Apr 12, 2023, 4:05 PM EDT - 1 year ago

Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference

Apr 5, 2023, 8:00 AM EDT - 1 year ago

Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023

Mar 28, 2023, 8:00 AM EDT - 1 year ago

Immuneering Appoints Harold E. Brakewood as Chief Business Officer

Mar 14, 2023, 4:30 PM EDT - 2 years ago

Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023

Mar 6, 2023, 10:50 PM EST - 2 years ago

Immuneering Corporation (IMRX) Q4 2022 Earnings Call Transcript

Mar 6, 2023, 4:05 PM EST - 2 years ago

Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Mar 5, 2023, 6:30 PM EST - 2 years ago

Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity

Feb 28, 2023, 8:00 AM EST - 2 years ago

Immuneering Announces Participation in March Investor Conferences

Feb 27, 2023, 8:00 AM EST - 2 years ago

Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Jan 31, 2023, 6:50 AM EST - 2 years ago

Immuneering To Present at Guggenheim 2023 Oncology Conference

Jan 18, 2023, 1:58 PM EST - 2 years ago

7 Cheap But Risky Biotech Stocks

AFMD BCAB NKTX TIL

Nov 28, 2022, 6:50 AM EST - 2 years ago

Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations